From: Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
N = 361 | Without bevacizumab (n = 176) | With bevacizumab (n = 185) | Combination chemotherapy (n = 219) | Single-agent chemotherapy (n = 142) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
N | (%) | N | (%) | P-value | N | (%) | N | (%) | P-value | |
Gender | 0.69 | 0.33 | ||||||||
Male | 75 | (43) | 72 | (41) | 126 | (58) | 89 | (63) | ||
Female | 101 | (57) | 113 | (59) | 93 | (42) | 53 | (37) | ||
Age (years) | <0.0001 | <0.0001 | ||||||||
< 60 | 36 | (20) | 57 | (31) | 71 | (32) | 24 | (17) | ||
60–75 | 91 | (52) | 111 | (60) | 128 | (59) | 72 | (51) | ||
≥ 75 | 49 | (28) | 17 | (9) | 20 | (9) | 46 | (32) | ||
Comorbidity | <0.001 | <0.01 | ||||||||
No | 50 | (28) | 81 | (44) | 38 | (28) | 91 | (42) | ||
1 comorbid condition | 49 | (28) | 56 | (30) | 36 | (26) | 66 | (30) | ||
≥ 2 comorbid conditions | 63 | (36) | 33 | (18) | 52 | (36) | 44 | (20) | ||
Unknown | 14 | (8) | 15 | (8) | 14 | (19) | 18 | (8) | ||
Primary tumor localization | 0.13 | |||||||||
Rectum | 68 | (39) | 85 | (46) | 107 | (49) | 47 | (33) | <0.01 | |
Colon | 108 | (61) | 100 | (54) | 112 | (51) | 95 | (67) | ||
Adjuvant chemotherapy | 0.34 | <0.01 | ||||||||
No | 103 | (59) | 100 | (54) | 137 | (63) | 67 | (47) | ||
Yes | 73 | (41) | 85 | (46) | 82 | (37) | 75 | (53) | ||
Time to metastases (years) | 0.12 | 0.59 | ||||||||
< 1 year | 57 | (32) | 43 | (23) | 57 | (26) | 42 | (30) | ||
1–2 years | 56 | (32) | 71 | (38) | 82 | (37) | 46 | (32) | ||
≥ 2 years | 63 | (36) | 71 | (38) | 80 | (37) | 54 | (38) | ||
Period of diagnosis metastases | <0.01 | 0.81 | ||||||||
2005–2006 | 70 | (40) | 41 | (22) | 69 | (31) | 42 | (30) | ||
2007–2008 | 57 | (32) | 78 | (42) | 83 | (38) | 52 | (37) | ||
2009–2011 | 49 | (28) | 66 | (36) | 67 | (31) | 48 | (34) | ||
Number of organs affected | 0.29 | 0.39 | ||||||||
1 organ | 72 | (41) | 85 | (46) | 92 | (42) | 65 | (46) | ||
2 organs | 69 | (39) | 59 | (32) | 83 | (38) | 44 | (31) | ||
≥ 3 organs | 35 | (20) | 41 | (22) | 44 | (20) | 33 | (23) | ||
First-line chemotherapy | <0.0001 | |||||||||
Single agent chemotherapy | 110 | (63) | 32 | (27) | ||||||
Combination chemotherapy | 66 | (37) | 153 | (83) | ||||||
Bevacizumab | <0.0001 | |||||||||
Yes | 153 | (70) | 32 | (23) | ||||||
No | 66 | (30) | 110 | (77) |